Overactive Bladder News, Treatment Studies | OAB Research Articles

Overactive Bladder (OAB)

OVERACTIVE BLADDER (OAB)

Vibegron Under Review for Overactive Bladder Treatment

The FDA has accepted for review the New Drug Application for vibegron (Urovant Sciences) for the treatment of patients with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

NDA Submitted for Vibegron for Overactive Bladder Treatment

Urovant Sciences has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for vibegron, a beta-3 adrenergic agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. The NDA submission includes data from an extensive clinical development program involving over 4000 patients with…

Dementia Tied to Anticholinergic Use

In a prospective study, the odds of dementia increased nearly 50% with daily use of anticholinergics for 3 years at the minimum effective dose recommended for older adults.
Patients with refractory OAB most likely represent a minority of the total OAB population.

AUA Updates Overactive Bladder Guideline

Updated OAB guideline now says clinicians may consider combination therapy with an antimuscarinic and beta3-andrenoceptor agonist for patients refractory to monotherapy with either of those medications.
Next post in Overactive Bladder (OAB)